share_log

TD Cowen Initiates Coverage On Standard BioTools With Buy Rating, Announces Price Target of $3.5

Benzinga ·  Apr 16 19:15

TD Cowen analyst Daniel Brennan initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price Target of $3.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment